Finoriq research workspace
Bone Biologics Corp (BBLG) SEC Filings & Filing Highlights
Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which. Review BBLG SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
- Company
- Bone Biologics Corp (BBLG)
- Ticker
- BBLG
- Market Cap
- $2M
- Latest Price
- $1.13
- Industry
- Industrial Specialties
Bone Biologics Corp (BBLG) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Bone Biologics Corp (BBLG).
| Event | Form | Date |
|---|---|---|
| Bone Biologics Corp: Corporate updateOn March 13, 2026, Bone Biologics Corporation (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the U.S. Sec... | 8-K8.01 | 2026-03-13 |
| Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provid...Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook | 8-K7.01 | 2026-01-08 |
| Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and OutlookBone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook | 8-K7.01 | 2025-09-04 |
| Bone Biologics Announces Pricing of $5.0 Million Public OfferingBone Biologics Announces Pricing of $5.0 Million Public Offering | 8-K8.01 | 2025-06-30 |
| Bone Biologics Corp: Material agreementOn June 27, 2025, Bone Biologics Corporation (the “Company”) priced a public offering (the “Offering”) of (i) 793,750 shares (the “Shares”)... | 8-K1.01 | 2025-06-30 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.